Epigral is planning a target revenue of ₹5000 crore by 2030-31, aided by upcoming production scale-ups in CPVC Resin and Epichlorohyrdin (ECH). The company expects to reach Rs 2,900 crore in revenue this fiscal year following revenue of Rs 2,500-2,530 crore in 2026. Capacity expansions for CPVC Resin and ECH will commence soon, contributing partially this year and more significantly in the next fiscal year.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.